Literature DB >> 23443340

Additive prognostic value of the SYNTAX score over GRACE, TIMI, ZWOLLE, CADILLAC and PAMI risk scores in patients with acute ST-segment elevation myocardial infarction treated by primary percutaneous coronary intervention.

Voin Brkovic1, Milan Dobric, Branko Beleslin, Vojislav Giga, Vladan Vukcevic, Sinisa Stojkovic, Goran Stankovic, Milan A Nedeljkovic, Dejan Orlic, Miloje Tomasevic, Jelena Stepanovic, Miodrag Ostojic.   

Abstract

This study evaluated additive prognostic value of the SYNTAX score over GRACE, TIMI, ZWOLLE, CADILLAC and PAMI risk scores in patients with ST-segment elevation myocardial infarction (STEMI) undergoing primary percutaneous coronary intervention (pPCI). All six scores were calculated in 209 consecutive STEMI patients undergoing pPCI. Primary end-point was the major adverse cardiovascular event (MACE--composite of cardiovascular mortality, non-fatal myocardial infarction and stroke); secondary end point was cardiovascular mortality. Patients were stratified according to the SYNTAX score tertiles (≤12; between 12 and 19.5; >19.5). The median follow-up was 20 months. Rates of MACE and cardiovascular mortality were highest in the upper tertile of the SYNTAX score (p < 0.001 and p = 0.003, respectively). SYNTAX score was independent multivariable predictor of MACE and cardiovascular mortality when added to GRACE, TIMI, ZWOLLE, and PAMI risk scores. However, the SYNTAX score did not improve the Cox regression models of MACE and cardiovascular mortality when added to the CADILLAC score. The SYNTAX score has predictive value for MACE and cardiovascular mortality in patients with STEMI undergoing primary PCI. Furthermore, SYNTAX score improves prognostic performance of well-established GRACE, TIMI, ZWOLLE and PAMI clinical scores, but not the CADILLAC risk score. Therefore, long-term survival in patients after STEMI depends less on detailed angiographical characterization of coronary lesions, but more on clinical characteristics, myocardial function and basic angiographic findings as provided by the CADILLAC score.

Entities:  

Mesh:

Year:  2013        PMID: 23443340     DOI: 10.1007/s10554-013-0202-1

Source DB:  PubMed          Journal:  Int J Cardiovasc Imaging        ISSN: 1569-5794            Impact factor:   2.357


  31 in total

1.  Usefulness of the SYNTAX score to predict "no reflow" in patients treated with primary percutaneous coronary intervention for ST-segment elevation myocardial infarction.

Authors:  Michael Magro; Sjoerd T Nauta; Cihan Simsek; Eric Boersma; Elco van der Heide; Evelyn Regar; Ron T van Domburg; Felix Zijlstra; Patrick W Serruys; Robert Jan van Geuns
Journal:  Am J Cardiol       Date:  2011-12-15       Impact factor: 2.778

2.  Recommendations for chamber quantification: a report from the American Society of Echocardiography's Guidelines and Standards Committee and the Chamber Quantification Writing Group, developed in conjunction with the European Association of Echocardiography, a branch of the European Society of Cardiology.

Authors:  Roberto M Lang; Michelle Bierig; Richard B Devereux; Frank A Flachskampf; Elyse Foster; Patricia A Pellikka; Michael H Picard; Mary J Roman; James Seward; Jack S Shanewise; Scott D Solomon; Kirk T Spencer; Martin St John Sutton; William J Stewart
Journal:  J Am Soc Echocardiogr       Date:  2005-12       Impact factor: 5.251

3.  Universal definition of myocardial infarction.

Authors:  Kristian Thygesen; Joseph S Alpert; Harvey D White
Journal:  Eur Heart J       Date:  2007-10       Impact factor: 29.983

4.  Usefulness of the SYNTAX score for predicting clinical outcome after percutaneous coronary intervention of unprotected left main coronary artery disease.

Authors:  Davide Capodanno; Maria Elena Di Salvo; Glauco Cincotta; Marco Miano; Claudia Tamburino; Corrado Tamburino
Journal:  Circ Cardiovasc Interv       Date:  2009-06-30       Impact factor: 6.546

5.  5-year clinical outcomes of the ARTS II (Arterial Revascularization Therapies Study II) of the sirolimus-eluting stent in the treatment of patients with multivessel de novo coronary artery lesions.

Authors:  Patrick W Serruys; Yoshinobu Onuma; Scot Garg; Pascal Vranckx; Bernard De Bruyne; Marie-Claude Morice; Antonio Colombo; Carlos Macaya; Gert Richardt; Jean Fajadet; Christian Hamm; Monique Schuijer; Tessa Rademaker; Kristel Wittebols; Hans Peter Stoll
Journal:  J Am Coll Cardiol       Date:  2010-02-18       Impact factor: 24.094

6.  The Thrombolysis in Myocardial Infarction (TIMI) trial. Phase I findings.

Authors: 
Journal:  N Engl J Med       Date:  1985-04-04       Impact factor: 91.245

7.  Prediction of mortality after primary percutaneous coronary intervention for acute myocardial infarction: the CADILLAC risk score.

Authors:  Amir Halkin; Mandeep Singh; Eugenia Nikolsky; Cindy L Grines; James E Tcheng; Eulogio Garcia; David A Cox; Mark Turco; Thomas D Stuckey; Yingo Na; Alexandra J Lansky; Bernard J Gersh; William W O'Neill; Roxana Mehran; Gregg W Stone
Journal:  J Am Coll Cardiol       Date:  2005-05-03       Impact factor: 24.094

8.  Prediction of 1-year clinical outcomes using the SYNTAX score in patients with acute ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention: a substudy of the STRATEGY (Single High-Dose Bolus Tirofiban and Sirolimus-Eluting Stent Versus Abciximab and Bare-Metal Stent in Acute Myocardial Infarction) and MULTISTRATEGY (Multicenter Evaluation of Single High-Dose Bolus Tirofiban Versus Abciximab With Sirolimus-Eluting Stent or Bare-Metal Stent in Acute Myocardial Infarction Study) trials.

Authors:  Scot Garg; Giovanna Sarno; Patrick W Serruys; Alfredo E Rodriguez; Leonardo Bolognese; Maurizio Anselmi; Nicoletta De Cesare; Salvatore Colangelo; Raul Moreno; Stefania Gambetti; Monia Monti; Laura Bristot; Marco Bressers; Hector M Garcia-Garcia; Giovanni Parrinello; Gianluca Campo; Marco Valgimigli
Journal:  JACC Cardiovasc Interv       Date:  2011-01       Impact factor: 11.195

9.  Assessment of the SYNTAX score in the Syntax study.

Authors:  Patrick W Serruys; Yoshinobu Onuma; Scot Garg; Giovanna Sarno; Marcel van den Brand; Arie-Pieter Kappetein; Nic Van Dyck; Michael Mack; David Holmes; Ted Feldman; Marie-Claude Morice; Antonio Colombo; Eric Bass; Katrin Leadley; Keith D Dawkins; Gerrit-Anne van Es; Marie-Angèle M Morel; Friedrich W Mohr
Journal:  EuroIntervention       Date:  2009-05       Impact factor: 6.534

10.  Prognostic assessment of patients with acute myocardial infarction treated with primary angioplasty: implications for early discharge.

Authors:  Giuseppe De Luca; Harry Suryapranata; Arnoud W J van 't Hof; Menko-Jan de Boer; Jan C A Hoorntje; Jan-Henk E Dambrink; A T Marcel Gosselink; Jan Paul Ottervanger; Felix Zijlstra
Journal:  Circulation       Date:  2004-05-24       Impact factor: 29.690

View more
  9 in total

Review 1.  Cardiovascular imaging 2013 in the International Journal of Cardiovascular Imaging.

Authors:  Hiram G Bezerra; Ricardo A Costa; Johan H C Reiber; Frank J Rybicki; Paul Schoenhagen; Arthur A Stillman; Johan De Sutter; Nico R L Van de Veire
Journal:  Int J Cardiovasc Imaging       Date:  2014-04       Impact factor: 2.357

2.  Prognostic factors of in-hospital mortality in all comers with ST elevation myocardial infarction undergoing primary percutaneous coronary intervention.

Authors:  Songsak Kiatchoosakun; Chaiyasith Wongwipaporn; Burabha Pussadhamma
Journal:  Heart Asia       Date:  2016-06-14

3.  The relationship between neutrophil to lymphocyte ratio, platelet to lymphocyte ratio and thrombolysis in myocardial infarction risk score in patients with ST elevation acute myocardial infarction before primary coronary intervention.

Authors:  Halit Acet; Faruk Ertaş; Mehmet Zihni Bilik; Mehmet Ata Akıl; Ferhat Özyurtlu; Mesut Aydın; Mustafa Oylumlu; Nihat Polat; Murat Yüksel; Abdulkadir Yıldız; Hasan Kaya; Abdurrahman Akyüz; Hilal Ayçiçek; Mehmet Özbek; Nizamettin Toprak
Journal:  Postepy Kardiol Interwencyjnej       Date:  2015-06-22       Impact factor: 1.426

4.  ACTION (acute coronary treatment and intervention outcomes network) registry-GWTG (get with the guidelines) risk score predicts long-term mortality in acute myocardial infarction.

Authors:  Tongtong Yu; Chunyang Tian; Jia Song; Dongxu He; Zhijun Sun; Zhaoqing Sun
Journal:  Oncotarget       Date:  2017-10-11

5.  Comparison of the TIMI, GRACE, PAMI and CADILLAC risk scores for prediction of long-term cardiovascular outcomes in Taiwanese diabetic patients with ST-segment elevation myocardial infarction: From the registry of the Taiwan Society of Cardiology.

Authors:  Yung-Ta Kao; Yi-Chen Hsieh; Chien-Yi Hsu; Chun-Yao Huang; Ming-Hsiung Hsieh; Yung-Kuo Lin; Jong-Shiuan Yeh
Journal:  PLoS One       Date:  2020-02-13       Impact factor: 3.240

6.  Residual SYNTAX II Score and long-term outcomes post-ST-elevation myocardial infarction in an urban US cohort: the Montefiore STEMI Registry.

Authors:  Anna E Bortnick; Sanyog G Shitole; Hayder Hashim; Pankaj Khullar; Michael Park; Michael Weinreich; Stephen Seibert; Judah Rauch; Giora Weisz; Jorge R Kizer
Journal:  Coron Artery Dis       Date:  2022-05-01       Impact factor: 1.717

7.  Prognostic value of blood count parameters in patients with acute coronary syndrome.

Authors:  Arsalan Majeed Adam; Ather Hasan Rizvi; Amna Haq; Rabia Naseem; Aiman Rehan; Ali Tariq Shaikh; Abdul Haseeb Abbas; Ansab Godil; Arif Ali; Muhammad Saad Ali Mallick; Muhammad Shahzeb Khan; Muhammad Nawaz Lashari
Journal:  Indian Heart J       Date:  2017-06-30

8.  ST-segment depression in left precordial leads in electrocardiogram of patients with acute inferior myocardial infarction undergoing primary percutaneous coronary intervention.

Authors:  Hossein Namdar; Leyla Imani; Samad Ghaffari; Naser Aslanabadi; Najmeh Reshadati; Zhila Samani; Ghiti Davarmoin; Naser Moayyednia; Yalda Nazer; Shahla Sarhangzadeh; Ahmad Separham
Journal:  Interv Med Appl Sci       Date:  2018-12

9.  Prognosis evaluation of universal acute coronary syndrome: the interplay between SYNTAX score and ApoB/ApoA1.

Authors:  Xiaotong Wang; Zhongyu Wang; Bing Li; Ping Yang
Journal:  BMC Cardiovasc Disord       Date:  2020-06-15       Impact factor: 2.298

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.